Journal of Clinical Investigation

OCT 14, 2026 · JOURNAL ARTICLE

Insulin sensitivity and mitochondrial homeostasis connect lactation to maternal metabolic health

Journal of Clinical Investigation

Lactation insufficiency in postpartum women has been associated with obesity and insulin resistance, among other risk factors. Challenges related to translating findings from anima

OCT 14, 2026 · JOURNAL ARTICLE

Edited HSPCs rescue frataxin deficiency and inflammation-driven multisystemic pathology in Friedreich’s ataxia mice

Journal of Clinical Investigation

Friedreich’s ataxia (FRDA) is a multisystemic neurodegenerative disorder caused by GAA repeat expansion in intron 1 of frataxin ( FXN ), resulting in FXN deficiency and mitochondri

OCT 14, 2026 · JOURNAL ARTICLE

Next-generation CDK inhibitors in HR+/HER2– breast cancer

Journal of Clinical Investigation

Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth fa

OCT 14, 2026 · JOURNAL ARTICLE

Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment

Journal of Clinical Investigation

One in eight women will be diagnosed with breast cancer in their lifetime. Most breast cancers express estrogen receptor α (ERα) and depend on its signaling, which promotes tumor g

OCT 14, 2026 · JOURNAL ARTICLE

Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2– breast cancer

Journal of Clinical Investigation

BACKGROUND We previously defined 4 hormone receptor + /human epidermal growth factor receptor 2 – (HR + /HER2 – ) subtypes: SNF1 canonical luminal, SNF2 immunogenic, SNF3 prolifera

OCT 14, 2026 · JOURNAL ARTICLE

PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance

Journal of Clinical Investigation

Somatic alterations in the phosphoinositide 3-kinase (PI3K) pathway are frequent oncogenic drivers in cancer and are particularly relevant in estrogen receptor–positive breast canc

OCT 13, 2026 · JOURNAL ARTICLE

Combined inhibition of DNA Polymerase Theta and ATR targets MYBL2-high triple-negative breast cancer stem cells

Journal of Clinical Investigation

Triple negaJve breast cancer (TNBC) is characterised by poor prognosis and limited treatment opJons, parJally due to therapy-resistant stem/progenitor cells driving metastasis. Ele

SEP 30, 2026 · JOURNAL ARTICLE

Antibody-drug conjugates in breast cancer: redefining targeted therapy

Journal of Clinical Investigation

Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer and redefined the conceptual distinction between targeted therapy and conventional chemoth